Senomyx
AcquiredGeneva, CH Β· 28,619 employees on LinkedIn Β· 3 known investors
Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions. The company serves customers in the nutrition, health, and beauty industries focused on sustainability and consumer needs.
Also known as Ambryx, Inc. Β· Senomyx, Inc. Β· SNMX
Founders & leadership
Investors Β· 3
Company profile
researched Aug 2026Senomyx, Inc. was an American biotechnology company headquartered in San Diego (originally La Jolla), California, that applied genomics and receptor biology to the discovery and development of novel flavor ingredients, flavor enhancers and natural high-intensity sweeteners for the food, beverage and ingredient supply industries. The company built proprietary taste receptor-based assays covering sweet, savory (umami), salt and bitter taste, using them to screen large compound libraries for molecules that modify taste perception at very low use levels, enabling reduced sugar, salt and monosodium glutamate content while retaining sensory quality.
Commercially, Senomyx sold flavor ingredients under its Complimyx brand, including Sweetmyx, Savorymyx and Bittermyx, through a direct sales program to flavor companies, and worked under collaboration and partnership agreements with large global food, beverage and ingredient companies. Its stated division of responsibility with collaborators placed discovery, development and regulatory approval with Senomyx, while partners handled manufacturing, marketing, sales and distribution of consumer products containing its ingredients. Late in its independent life the company identified and began developing Siratose, a high-intensity, clean-tasting sweetener naturally occurring in monk fruit.
Senomyx traded on the NASDAQ Global Select Market under the ticker SNMX until Firmenich acquired it in 2018 via a cash tender offer and second-step merger, after which Senomyx was integrated into Firmenich's North America R&D organization with research operations remaining in San Diego.
Founding story
The company was incorporated in Delaware in September 1998 as Ambryx, Inc. and commenced operations in January 1999, based in La Jolla, California; it changed its name to Senomyx in 2000. Its founding group centered on Stanford neurobiology professor Lubert Stryer, who had earlier co-founded Affymetrix and Aurora Biosciences and became interested in the commercial potential of smell and taste receptor research. He was joined by UCSD scientists Charles Zuker, who identified proteins used to detect bitter and sweet tastes, and Roger Tsien; Wikipedia additionally names Paul Nevsky as a co-founder. Paul Grayson, previously senior vice-president of corporate development at Aurora Biosciences, was recruited to lead the company and bring its compounds through discovery, development and commercialization.
Business model
Senomyx combined a direct sales program, selling Complimyx-branded flavor ingredients (Sweetmyx, Savorymyx, Bittermyx) to flavor companies, with collaboration agreements under which it performed discovery, development and regulatory approval work while partner consumer-products companies manufactured, marketed, sold and distributed the finished products containing its ingredients.
Revenue derived from ingredient sales to flavor companies and from collaboration agreements with packaged food and beverage partners. The company reported sales of $9.3 million in 2005 and total revenues of $3.3 million in the second quarter ended 30 June 2018.
Traction
By 2005 the company had 93 employees and sales of $9.3 million, with research collaborations with five of the largest packaged food and beverage companies. Nestle commercialized savory flavors using its technology in 2007 and Sweetmyx obtained approval in 2014. For the second quarter ended 30 June 2018 Senomyx reported total revenues of $3.3 million, a net loss of $3.6 million, no debt and $14.7 million in cash, with 48,338,277 shares of common stock outstanding as of 26 July 2018.
Latest developments
Firmenich completed the acquisition of Senomyx on 2 November 2018 through a tender offer at $1.50 per share and a subsequent second-step merger, integrating Senomyx into its North America R&D organization and commercializing the products through its Taste Platform. Firmenich later combined with DSM to form dsm-firmenich, a publicly listed nutrition, health and beauty company with over EUR 9 billion in sales from continuing operations, roughly 20% adjusted EBITDA margin and about 21,000 employees, whose shares began dual trading on the SIX Swiss Exchange alongside Euronext Amsterdam in May 2026.
βΈFull profile β market position, technology, go-to-market, geography, history, risks & controversies
Market position
Firmenich described Senomyx as a leader in taste innovation and a pioneer in sweet, cooling and bitter solutions, and its acquisition as strengthening Firmenich's taste and nutrition capabilities. Senomyx was one of a small number of companies applying receptor-based screening to flavor discovery for the packaged food and beverage industry.
Rather than developing artificial substitutes, Senomyx used genomic and receptor-based assays to identify allosteric modulators that enhance existing taste perception at very low concentrations, an approach requiring a shorter and less costly regulatory path (FEMA GRAS recommendation) than pharmaceutical development.
Technology
The core technology engineered human embryonic kidney (HEK-293) cells to express human taste receptors and ion channels, including the T1R2/T1R3 sweet receptor heterodimer, T1R1/T1R3 for umami, T2R-family bitter receptors and epithelial sodium channels for saltiness. Receptor genes were cloned into expression vectors and transfected into HEK-293 cells, with chimeric or promiscuous G proteins co-expressed so that receptor activation could be read out as intracellular calcium increases detected by fluorescent dyes. These cell-based assays supported high-throughput screening of libraries exceeding 500,000 natural and synthetic compounds to find allosteric modulators that amplify or block taste signals; hits were then optimized for potency, stability, solubility and compatibility with food matrices. Related research also produced TRPM8 agonists used as cooling agents, one of which received FEMA GRAS status as FEMA 4809.
Go-to-market
Direct sales of Complimyx-branded ingredients to flavor companies combined with long-term discovery and development collaborations with major consumer packaged goods companies, whose partners commercialized the resulting consumer products.
Flavor companies and large packaged food, beverage, ingredient supply and oral care manufacturers seeking to reduce sugar, salt and MSG content while maintaining taste; named collaborators included The Coca-Cola Company, Kraft Foods, Nestle, Cadbury Schweppes, Campbell Soup Company and PepsiCo.
Geography
Headquartered and conducting research and development in San Diego / La Jolla, California, with collaborations with global food and beverage companies; after the acquisition its R&D operations remained in San Diego within Firmenich's North America R&D organization.
History
After several years of development-stage work, Senomyx established research collaborations with major packaged food and beverage companies, beginning with Kraft Foods in December 2000 and later including The Coca-Cola Company, Nestle, Cadbury Schweppes, Campbell Soup Company and PepsiCo. Around 2001 it patented taste receptor-based assay systems expressed in HEK293 human cell culture. Nestle commercialized savory flavors based on its technology in 2007, and its Sweetmyx sucrose enhancer received regulatory clearance in 2014. The company's shares declined after PepsiCo reversed a trial rollout of Senomyx ingredients in its sodas in 2016, and in June 2018 a shareholder pushed for change at the company. On 17 September 2018 Firmenich and Senomyx announced a definitive merger agreement at $1.50 per share in cash; the tender offer expired on 2 November 2018 with about 82.9% of shares tendered, and Senomyx became a wholly owned Firmenich subsidiary and was delisted from NASDAQ.
Risks & controversies
Senomyx's use of HEK-293 cell lines, derived from a human embryo aborted in 1973, to express taste receptors for screening drew objections from pro-life groups; in 2011 Children of God for Life issued an action alert calling for a boycott of companies partnering with Senomyx, and in 2012 an Oklahoma bill proposed by Ralph Shortey sought to prohibit the manufacture or sale of food or products using aborted human fetuses. The company maintained no fetal material was present in final products. Because its additives were used at very low levels (reportedly under one part per million) and classified as artificial flavors, they were not individually disclosed to consumers and had not undergone FDA safety approval. The share price declined after PepsiCo reversed a trial rollout of its ingredients in 2016, and a shareholder publicly pushed for change at the company in June 2018.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 10
launches, deals, and filingsSentry Merger Sub, Inc., a wholly owned subsidiary of Firmenich Incorporated, completed its tender offer at $1.50 per share with approximately 40,713,815 shares (82.9% of outstanding) tendered; the second-step merger under Delaware law made Senomyx a wholly owned Firmenich subsidiary and its common stock ceased trading on the NASDAQ Global Select Market.
$72M source β
Firmenich and Senomyx entered a definitive merger agreement under which Firmenich would acquire all outstanding Senomyx common stock for $1.50 per share in cash, a premium of about 43% over the 14 September 2018 closing price and about 39% over the prior 30-trading-day VWAP. Needham & Company and Conexus Capital Advisors advised Senomyx, with Cooley LLP as legal counsel; Piper Jaffray advised Firmenich, with Duane Morris LLP as legal counsel.
Senomyx identified and began developing Siratose, a high-intensity, clean-tasting sweetener that occurs naturally in monk fruit.
Reuters reported that a Senomyx shareholder was pushing for change at the flavor maker.
The company's stock declined after PepsiCo reversed a trial rollout of Senomyx ingredients in its sodas.
Grokipedia cites FDA approval for the Sweetmyx sucrose enhancer in 2014.
Stryer returned to his professorship at Stanford University and resigned from Senomyx while continuing as Chairman of the Scientific Advisory Board.
Senomyx established its first research collaboration, with Kraft Foods, to develop flavor molecules for food applications.
The company was incorporated in September 1998 as Ambryx, Inc. and commenced operations in January 1999 in La Jolla, California; it was renamed Senomyx, Inc. in 2000.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
βΈResearch sources Β· 8
primary sources listed
- Senomyxfirmenich.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Senomyx do?
- Senomyx was a San Diego biotechnology company discovering flavor ingredients and sweeteners via human taste receptor assays; acquired by Firmenich in 2018.
- Who are Senomyx's investors?
- Senomyx's investors include Bay City Capital, Prospect Venture Partners, Rho Ventures.
- Where is Senomyx headquartered?
- Senomyx is headquartered in Geneva, CH.